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Abstract: The raging ethical, religious, moral, political, and safety issues pertaining to the use of embryonic stem cells for therapy and
research have prompted researchers to develop possibly better alternatives that are more efficacious and serve multiple purposes. Induced
pluripotent stem cells (iPSCs) developed by multiple methods provide an unparalleled source of cells that could be differentiated into
progeny cells. In cell-based disease models the progeny cells mimic, at least in part, the pathology of the studied disease and are used to
improve the mechanistic understanding of the pathology. Furthermore, these cells could be used to test the efficacy and safety of drugs
that can reverse this phenotype. This review provides an overview of the aforesaid methods for iPSC generation and the development
of certain disease-based model systems. In this review, the focus is on model systems for neurological and hematological diseases. Last
but not least, the importance of the microenvironment is underscored and the significance of these model systems is discussed in the
context of drug screening and development.
Key words: Induced pluripotent stem cells, reprogramming methods, integrating/nonintegrating, induced pluripotent stem cell disease
models, neurological/hematological diseases, induced pluripotent stem cell microenvironment modeling, drug discovery/screening

1. Introduction
There are raging ethical, religious, moral, political, and
safety issues pertaining to the use of embryonic stem cells
for therapy and research. Moreover, the known variations,
including epigenetic factors, involving mouse stem cells
have led researchers to develop alternative methods to
obtain stem cells/stem cell-like cells. The Nobel Prizewinning effort of Shinya Yamanaka and his coworkers
involved the reprogramming of mouse skin fibroblasts
using retroviral-mediated transduction of genes encoding
for transcription factors (TFs). However, the limitations
pertaining to the extent and efficiency of reprogramming
as well as the possible promiscuous integration and tumor
formation have led researchers to refine the existing
methods (e.g., integration-free plasmid-based approaches)
and include chemicals that can possibly supplement and/
or replace the pivotal 4 TFs. Efforts are also ongoing to
develop and refine cell lines and reagent cocktails that are
intermediate in terms of their epigenetic state, between
the fully differentiated state and the development of stem
cell-like cells (induced pluripotent stem cells (iPSCs)).
In all of these cases, easily accessible and sampled
autologous fibroblasts have been the cell type of choice in
the development of disease models. Such models should
* Correspondence: p.k.suresh@vit.ac.in
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mimic the microenvironment and (at least in part) the
mechanisms of pathogenesis. This approach provides
an opportunity for the testing of drugs and chemicals,
including nanomaterials of biomedical and environmental
significance. In addition, these stem cells should satisfy
the criteria for pluripotency and should be positive for the
stem cell markers characteristic of the iPSC phenotype.
This review will also discuss the state-of-the art methods
(ex vivo and in vivo) to establish and maintain iPSCs.
Moreover, the focus will be on both disease modeling and
drug discovery and testing.
2. Currently available methods for reprogramming cells
to produce iPSCs
Somatic cell nuclear transfer (SCNT), a technique
pioneered by Gurdon et al. (1958), involved the transfer of
a mature cell’s nucleus into an enucleated egg; this egg was
eventually transformed into a living frog. Other researchers
showed that the epigenome of somatic cells (adult
thymocytes) could be reprogrammed by their fusion with
embryonic stem cells, inducing these somatic cells to
exhibit pluripotency in vivo (Tada et al., 2001). Further
refinements to improve the efficiency of reprogramming
involved fractionation of pluripotent stem cell-like cells
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from the differentiated cells. The nuclei from these cells
were able to reprogram oocytes at a higher efficiency (Pan
et al., 2015) and provided corroborative evidence for the
fundamental idea that the relatively undifferentiated cells
had a better reprogramming efficiency (Oback and Wells,
2007). These findings were also consistent with a study
wherein it was demonstrated that iPSC generation could
be enhanced (approximately eightfold increased) from a
subpopulation of SSEA3+ human dermal fibroblasts
(Byrne et al., 2009). Several methods are currently available
to reprogram adult cells and convert them to a stem cell
state that resembles that of embryonic stem cells. One of
the methods used often involves retroviral-mediated
transduction of TFs. These factors, used singly and/or in
combination with chemicals like Valproic acid (Huangfu
et al., 2008), have been used to dedifferentiate cells
including fibroblasts, neural stem cells, stomach cells, liver
cells, keratinocytes, amniotic cells, blood cells, and adipose
cells in order to produce stem cell-like cells (Robinton and
Daley, 2012). Their efficiency is low (0.001%–1%) and the
reprogramming is not complete. The other disadvantages
include a slow rate of conversion, nonspecific genomic
integration with the possibility of activating a latent
oncogene, and incomplete proviral silencing. Takahashi
and Yamanaka’s (2006) ground-breaking research findings
involved the initial screening of 24 TFs for their
reprogramming potential using a combination of reporter
gene technology and a neomycin resistance marker. The
resistance marker enabled the identification of cells with
the embryonic stem cell-like phenotype in which
reactivation of the embryo-specific genes had occurred.
Their experiments finally culminated in the identification
of 4 TFs (Oct-4, Sox-2, Klf-4, and c-Myc (OSKM)), which,
when transfected in combination, could reprogram mouse
embryonic fibroblasts (MEFs). Such cells were isolated
from Fbxβneo/βneo embryos and were stem cell-like cells.
However, their efficiency of conversion was relatively
lower. Their stem cell phenotype was inferred based on
morphology and marker gene expression; they developed
tumors following injection into nude mice and into
blastocysts for the development of germ layers (Takahashi
and Yamanaka, 2006). Subsequently, the same 4 factors
were used to reprogram human adult fibroblasts with the
aim to generate stem cells that could be used as patientspecific disease models. They were demonstrated to be
embryonic stem cells in terms of their shape, proliferation
potential, surface protein profile, gene expression,
epigenetics of the pluripotent cell-specific genes, activity
of the telomerase enzyme, and the ability to form the germ
layer (Takahashi et al., 2007). Another study provided
corroborative evidence for the role of ectopic expression of
the aforesaid 4 TFs in the reprogramming of dermal
fibroblasts; these reprogrammed cells resembled those of

the stem cell lineage in terms of morphology, gene
expression profile, and karyotypic stability (Lowry et al.,
2007). In both cases, the ability to form all 3 germ layers
was demonstrated. Integrating lentiviral vectors have also
been used to reprogram human somatic cells using a
different combination of the 4 TFs (OCT4, SOX2,
NANOG, and LIN28). The stem cells produced thereafter
exhibit a gene expression profile, surface antigenicity,
karyotype, and telomerase activity that are characteristic
of human embryonic stem cells. They have the capability
to develop into highly differentiated derivatives of all 3
primary germ layers. This may be the method of choice,
provided mutation as a result of viral integration is avoided
(Yu et al., 2007). Subsequently, lentiviral vectors were
genetically modified to conditionally express Oct-4, Sox-2,
Klf-4, and c-Myc under the control of the doxycyclineinducible reverse tetracycline transactivator (rtTA) (TetOn system). These vectors were transfected into a 2-day
explant culture of mouse pancreatic β cells (Rat Insulin
Promoter (RIP)-Cre/LacZ). After 24 days, an expansion in
80% of the colonies was observed with activation of the
pluripotency markers. Reprogramming efficiency ranged
from 0.1% to 0.2% and colony expansion was done in the
absence of doxycycline. The reprogrammed progeny from
terminally differentiated cells expressed markers
characteristic of pluripotent cells, formed teratomas, and
was capable of germ line transmission in chimeric animals
(Stadtfeld et al., 2008a). This doxycycline-inducible
lentivirus system was extended to improve the efficiency of
reprogramming in both primary and secondary hiPSCs
(from human fibroblasts and keratinocytes), unlike the
viral-mediated transduction (took several weeks for
human keratinocytes) (Maherali et al., 2008; Stadtfeld et
al., 2008b). A single mouse lentiviral cassette-based system
combining the mouse transcripts for all 4 factors using a
2A peptide and an internal ribosome entry site in postnatal
mouse tail-tip fibroblasts was a method that represented a
significant milestone in the reprogramming field. The
success of this method was determined based on
morphology, markers, ability to form germ layers in
teratoma assays, and chimera formation (Sommer et al.,
2009). Another group of researchers used a similar
approach to introduce human cDNAs for 3 TFs (Oct4,
Sox2, and Klf4) into adult dermal fibroblasts from a
humanized version of a mouse model system for sickle cell
disease, using a self-inactivating lentiviral (SIN) vector.
These genes were downstream of the elongation factor 1α
promoter with a porcine virus teschovirus-1 2A sequence
(ribosome skipping) between them. After 30 days, the
colonies exhibited markers for pluripotency (e.g.,
endogenous Oct4, Sox2, NANOG, alkaline phosphatase,
and stage-specific embryonic antigen-1 (SSEA-1)) and
were able to produce teratomas in immunocompromised

999

KRISHNAN / Turk J Biol
mice and chimeras in murine blastocysts. The inserted
vectors (3 of them) could be excised with the Cre/Lox
recombinase methodology and the LoxP site did not affect
coding, sequences, promoters, and regulatory elements
(Chang et al., 2009). Subsequently, a similar humanized
version of this single cassette lentiviral vector system was
developed for human cells. This system also had the
advantage of excising the transgenes subsequent to
reprogramming, due to the presence of a cleavable
integration site, apart from regulating TF expression. This
methodology was extended to skin fibroblasts from human
donors afflicted with various types of lung diseases (cystic
fibrosis, emphysema related to α-1 antitrypsin deficiency)
apart from scleroderma and sickle-cell disease. Diseasespecific iPSCs that had the potential to produce tissues
that were endodermal in origin were generated (Somers et
al., 2010). This method provides an approach for the
controlled expression of TFs, in addition to enabling their
transduction into dividing and nondividing cells. However,
genomic integration and the requirement of transactivator
expression are limitations of this method. The issue of
promiscuous, potentially damaging, vector integrationmediated mutational events have been circumvented by
the use of nonintegrating lentiviral systems and have been
adopted in currently ongoing clinical trials for the
treatment of various diseases (Kumar et al., 2011). These
vectors circumvent the problem of viral or plasmidmediated integration of genes encoding for the
reprogramming TFs in the host genome, thereby increasing
the risk of malignant transformation. Adenoviral vectors
have been used in both mouse and human systems. In
mouse systems (fibroblasts and liver cells) nonintegrating
adenoviruses can be used to introduce OSKM factors and
produces iPSCs. Characterization by measuring the DNA
methylation pattern, marker analysis, teratoma formation,
and formation of tissue of the germline lineage in chimeras
also provided evidence for the generation of cells of the
desired type (Stadtfeld et al., 2008c). In human embryonic
fibroblasts
(HEFs),
adenoviral-mediated
ectopic
expression of these factors (c-Myc, Klf4, Oct4, and Sox2)
produced 3 stable iPSC colonies (3/12) with the
characteristic morphology and markers as evidence for
their identity. There was no integration of the virus as
demonstrated using Southern blotting and PCR. These
cells could produce dopaminergic neurons in vitro.
Teratoma formation in 5 weeks was also seen in nonobese
diabetic/severe combined immunodeficiency (SCID) mice
following subcutaneous (SC) injection of each of these cell
lines (Zhou et al., 2009). In addition to nonintegrating
adenoviral systems, extrachromosomal plasmids have
been used. One plasmid carried cDNAs for OSK TFs,
while the other had the c-Myc oncogene. These plasmids
were transfected into MEFs to generate iPSCs which could
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produce teratomas and chimeras in appropriate test
systems. Most importantly, there was no evidence of viral
integration (Okita et al., 2008). A variation of this
experimental design with 4 plasmids, each harboring one
of the 4 key TFs (Oct-4, Sox-2, NANOG, and Lin-28
(OSNL)), was used for their transient expression. Since no
packaging vectors were used, the risk of generating virions
was circumvented. Moreover, there was no need for
subcloning for the identification of cells without exogenous
DNA or there were no stability/selection issues. There was
no integration and the cells were pluripotent, formed
teratomas, and were able to differentiate into cells that
resembled those of hepatocyte and cardiac lineages
(targeted differentiation) (Si-Tayeb et al., 2010). As an
alternative strategy for the generation of iPSCs, Sendai
viruses (a nonintegrating RNA virus) can be used. The
resultant cells were pluripotent and their demethylation
pattern was characteristic of cells of this type. Enrichment
of those virus-free reprogrammed cells was accomplished
by using antibodies that recognized and eliminated those
cells that expressed a surface marker (HN) present on
Sendai virus-infected cells. Subsequently, germ layer
differentiation and targeted development into cells like
beating cardiomyocytes, neurons, and bone and pancreatic
cells were demonstrated (Fusaki et al., 2009). As an
alternative virus-independent “simplified” strategy to
reprogram HEFs and produce stable iPSC lines, the
PiggyBack (PB) transposon/transposase system was used
to deliver the Dox-inducible TF payload to fibroblasts.
Induced pluripotency was demonstrated by the expression
of markers as well as the propensity of these cells to
differentiate. Seamless excision was also demonstrated in
murine iPSC lines in which TFs were joined by 2A
sequences. This method has an efficiency of 0.1% and no
genomic integration was observed. However, several cell
lines would have to be screened subsequent to the
transfection (Woltjen et al., 2009). In a major step forward
in terms of avoiding the use of both chemicals and genes,
recombinant proteins for the 4 key TFs (OSKM) fused to a
cell-penetrating peptide (CPP) were introduced into
human fibroblasts. The resultant cells (iPSCs) were similar
to human embryonic stem cells in terms of morphology
and markers and were maintained for 35 passages.
Furthermore, they were capable of germ layer formation in
vitro and formed teratomas in vivo (Kim et al., 2009). The
risk of introducing potential harmful virally-mediated
genetic material was totally eliminated. In addition to its
safety, this method is fast and avoids the time-consuming
selection of potentially integration-free iPSCs. Lastly,
research and/or industrial centers that have an established
recombinant protein production system can use this
approach to produce iPSCs from these “chemicallydefined” reprogramming proteins in a cost-effective
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manner (Zhou et al., 2009). Nonintegrating synthetic RNA
has been used to efficiently differentiate RNA-iPSC
pluripotent stem cells (RiPSCs) into mature myogenic
cells. This approach is safer than viral/other genetic
approaches and the efficiency is also higher (approximately
2%, which is better by two orders of magnitude).
Embryonic stem-like colonies appeared in 17 days in
contrast with the 4 week period for viral-mediated
approaches. The in vitro transcript had a 5’ guanosine cap
and 5’ (with a strong Kozak translational initiation signal
sequence) and α-globin 3’ untranslated region (UTR) to
improve its half-life and its translational efficiency (Warren
et al., 2010). This construct was shown to bypass the innate
antiviral responses. The kinetics and efficiency of
reprogramming was better (with a range of about ~1%–
4.4%) without genomic integration. miRNA-based
strategies can improve the efficiency of the process by two
orders of magnitude. This reprogramming was
demonstrated by the formation of iPSCs (induction of
Oct4 expression) following the introduction of miRNA302
(miR302/367 cluster) in both mouse and human somatic
cells. The efficiency of this reprogramming process was
also dependent on the decreased expression of HDAC2
(Anokye-Danso et al., 2007). Another paper provided
corroborative evidence for the involvement of specific
microRNAs. In this regard, a combination of microRNAs
(mir-200c plus mir-302s and mir-369s family of mature
double stranded microRNAs) was involved in the
reprogramming process. This method has the obvious
advantage of not having to employ viral-based strategies
(Miyoshi et al., 2011). A summary of this section is
provided in Table 1.
3. Disease modeling using iPSCs: focus on neurological
and hematological diseases
3.1. Neurological models
Amyotrophic lateral sclerosis (ALS) is a heterogeneous
neurodegenerative disease that is progressive in nature
and affects the motor neurons of the brain and spinal cord.
Of the cases that exhibit the inherited form of the disease,
20% have a point mutation in the Cu/Zn SOD1 genes.
There are transgenic rodents that carry the mutant human
SOD1 genes with amino acid substitutions in G93A,
G85R, and G37R. This model system mimics the clinical
and histopathological features of the human disease
(Julien and Kriz, 2006) despite the lack of suitable animal
models for all types of this disorder. Furthermore, it has
been observed that transplantation of stem cell-derived
astrocytes or astrocyte precursor cells can home in and
restore the functional capabilities of this dysfunctional cell
type in vivo (Nicaise et al., 2015). Due to their excellent
therapeutic potential, patient-specific motor neurons
derived from iPSCs offer an excellent opportunity to be

used as models for the different subsets of ALS. Moreover,
this iPSC model can help in better understanding the
relative contribution of the microenvironment (support
cells) around the regenerating motor neuron. The fully
defined iPSCs could also be used for drug testing and
for generating autologous cells for therapy (Dimos et al.,
2008; Richard and Maragakis, 2015). The membranes of
iPSC-derived motor neurons from patients with ALS were
hyperexcitable due to delayed rectifier potassium current.
This pathology was corrected by using an activator of the
potassium channel (retigabine) in terms of improving
the survival of motor neurons with the mutations in the
SOD1 gene (Wainger et al., 2014). Human fibroblastderived iPSCs from ALS patients carried a TAR DNAbinding protein 43 (TDP-43) M337V mutation and they
were differentiated into functional motor neurons. The
relevance of this ex vivo system was underscored by
the demonstration of the presence of similar mutations
(mutations in transactive response DNA binding protein
43 kDa –TARDP) in patients with ALS-mediated
neurodegeneration and misaccumulation of TDP-43.
Such mutant neurons had a decreased survival and were
more sensitive to chemical (LY294002)-mediated selective
PI3K inhibition (Bilican et al., 2012). A motor neuron
cellular model was developed from fibroblasts isolated
from sporadic ALS patients. These neurons were able to
mimic the pathology (TDP-43 protein aggregation) seen
in vivo in postmortem tissue from one of the patients,
which was the source of iPSCs (Burkhardt et al., 2013).
Parkinson’s disease (PD) is the second most common
human degenerative disease with the loss of dopamineproducing neurons in the substantia nigra. It has been
classified broadly into the familial and sporadic forms.
In both cases the presence of a strong genetic component
and the lack of a cure for this disease have prompted
researchers to develop disease models in a dish. This was
made possible subsequent to the differentiation of iPSCs
into motor neurons in vitro to mimic, at least in part, the
mode of pathogenesis of PD (Badger et al., 2014). An iPSC
cell lines with a homozygous p.G2019S mutation in the
leucine-rich repeat kinase 2 (LRRK2) gene was produced.
Another cell line carried a full gene triplet repeat of the
α-synuclein encoding gene and synuclein alpha was
generated. These DA neurons from these two cell lines
were considered to be good models for early PD (Byers et
al., 2012). Mutations in the aforesaid gene for LRKK2 in the
mitochondrial genome of a PD patient have been known
to increase the susceptibility of iPSC-derived neural cells
to DNA damage due to oxidative stress. Individuals that
harbor homozygous or heterozygous LRRK2 G2019S
mutations, or those individuals carrying the heterozygous
LRRK2 R1441C (susceptibility marker) had higher levels
of mtDNA damage than unrelated healthy individuals. The
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Table 1. Currently available methods for reprogramming cells to produce iPSCs (from section 2 of this paper).
Sl. No. Reprogramming method

Citation details

1

SCNT-transfer of a mature cell’s nucleus into an enucleated egg

Gurdon et al., 1958

2

Cell fusion, fusion of adult thymocytes with embryonic stem cells, epigenome reprogramming,
Tada et al., 2001
pluripotency in vivo

3a

Relatively undifferentiated cells, better reprogramming efficiency

Oback and Wells, 2007

3b

Fractionation of subpopulation of SSEA3+ human dermal fibroblasts, iPSC generation could
be enhanced (approximately eightfold increase)

Byrne et al., 2009

3c

Fractionation of pluripotent stem cell-like cells from the differentiated cells, improvements in
reprogramming efficiency

Pan et al., 2015

4a

Reprogramming, combination of transcription factors + epigenetic modifier

Huangfu et al., 2008

4b

Dedifferentiation into stem cell-like cells, fibroblasts, neural stem cells, stomach cells, liver
cells, keratinocytes, amniotic cells, blood cells and adipose cells

Robinton and Daley, 2012

5a

Identification of 4 TFs (Oct-4, Sox-2, Klf-4, and c-Myc (OSKM)), retroviral transduction,
reprogramming mouse embryonic fibroblasts (MEFs)

Takahashi and Yamanaka,
2006

5b

Identification of 4 TFs (Oct-4, Sox-2, Klf-4, and c-Myc (OSKM)), retroviral transduction,
human adult fibroblasts

Takahashi et al., 2007;
Lowry et al., 2007

6

Different combinations of 4 TFs (OCT4, SOX2, NANOG, and LIN28), integrating lentiviral
vectors, reprogram human somatic cells

Yu et al., 2007

7

Doxycycline-inducible reverse tetracycline transactivator (rtTA)-based lentiviral system,
conditionally express Oct-4, Sox-2, Klf-4, and c-Myc, 2-day explant culture of mouse
pancreatic β cell (Rat Insulin Promoter (RIP)-Cre/LacZ)

Stadtfeld et al., 2008

8

Doxycycline-inducible lentiviral system to convert primary human fibroblasts and
keratinocytes into human induced pluripotent stem cells

Maherali et al., 2008;
Stadtfeld et al., 2008

9

Single mouse lentiviral cassette-based system, mouse transcripts for all 4 factors using a
2A peptide as well as an internal ribosome entry site in postnatal mouse tail-tip fibroblasts,
morphology, markers, ability to form germ layers in teratoma assays, chimera formation

Sommer et al., 2009

10

Introduce human cDNAs for 3 TFs (Oct4, Sox2, and Klf4) into adult dermal fibroblasts from
a humanized version of a mouse model system for sickle cell disease, using a self-inactivating
lentiviral (SIN) vector, genes downstream of the elongation factor 1α promoter and a
porcine virus teschovirus-1 2A sequence (ribosome skipping) between them; after 30 days,
colonies exhibited markers for pluripotency (e.g., endogenous Oct4, Sox2, NANOG, alkaline Chang et al., 2009
phosphatase, stage-specific embryonic antigen-1 (SSEA-1)); were able to produce teratomas in
immunocompromised mice as well as chimeras in murine blastocysts; inserted vectors (3 of
them) could be excised with the Cre/Lox recombinase methodology and the LoxP site did not
affect coding, sequences, promoters, and regulatory elements.

11

A similar humanized version of this single cassette lentiviral vector system was developed
for human cells. This system also had the advantage of excising the transgenes subsequent to
reprogramming, due to the presence of a cleavable integration site, in addition to regulating TF
Somers et al., 2010
expression. This methodology was extended to skin fibroblasts from human donors afflicted
with various types of lung diseases (cystic fibrosis, emphysema related to α-1 antitrypsin
deficiency) in addition to scleroderma and sickle-cell disease. Disease-specific iPSCs were
generated and had the potential to produce tissues that were endodermal in origin.

12

The issues of promiscuous, potentially damaging, vector integration-mediated mutational
events have been circumvented by the use of nonintegrating lentiviral systems and have been
adopted in currently ongoing clinical trials for the treatment of various diseases.
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Table 1. (Continued).

13

Adenoviral vectors have been used in both mouse and human systems. In mouse systems
(fibroblasts and liver cells) nonintegrating adenoviruses can be used to introduce OSKM
factors and produce iPSCs. Characterization by measuring DNA methylation pattern, marker
analysis, teratoma formation, and formation of tissue of the germline lineage in chimeras also
provided evidence for the generation of the cells of the desired type.

14

In human embryonic fibroblasts (HEFs), adenoviral-mediated ectopic expression of these
factors (c-Myc, Klf4, Oct4, and Sox2) produced 3 stable iPSC colonies (3/12) with the
characteristic morphology and markers as evidence for their identity. There was no integration
Zhou et al., 2009
of the virus as demonstrated using Southern blotting and PCR. These cells could produce
dopaminergic neurons in vitro. Teratoma formation was also seen in 5 weeks in nonobese
diabetic SCID mice following SC injection of each of these cell lines.

15

Extrachromosomal plasmids have been used. One plasmid carried cDNAs for OSK TFs,
while the other had the c-Myc oncogene. These plasmids were transfected into MEFs to
generate iPSCs that could produce teratomas and chimeras in appropriate test systems. Most
importantly, there was no evidence of viral integration.

Okita et al., 2008

16

A variation of this experimental design with 4 plasmids each harboring one of the 4 key TFs
(OSNL) was used for their transient expression. Since no packaging vectors were used, the
risk of generating virions was circumvented. Moreover, there was no need for subcloning for
the identification of cells without exogenous DNA or there were no stability/selection issues.
There was no integration and the cells were pluripotent, formed teratomas that were able
to differentiate into cells that resembled those of hepatocyte and cardiac lineages (targeted
differentiation).

Si-Tayeb et al., 2010

17

As an alternative strategy for the generation of iPSCs, Sendai viruses (a nonintegrating RNA
virus) can be used. The resultant cells were pluripotent and their demethylation pattern was
characteristic of cells of this type. Enrichment of those virus-free reprogrammed cells was
Fusaki et al., 2009
accomplished by using antibodies that recognized and eliminated those cells that expressed
a surface marker (HN) present on Sendai virus-infected cells. Subsequently, germ layer
differentiation and targeted development into cells like beating cardiomyocytes, neurons, bone
and pancreatic cells were demonstrated.

18

As an alternative virus-independent “simplified” strategy to reprogram HEFs and produce
stable iPSC lines, the PiggyBack (PB) transposon/transposase system was used to deliver
the Dox-inducible TF payload to fibroblasts. Induced pluripotency was demonstrated by the
expression of markers and the propensity of these cells to differentiate. Seamless excision
was also demonstrated in murine iPSC lines in which TFs were joined by 2A sequences. This
method has an efficiency of 0.1% and no genomic integration was observed. However, several
cell lines would have to be screened subsequent to the transfection.

19

To avoid the use of both chemicals and genes, recombinant proteins for the 4 key TFs (OSKM),
fused to a cell-penetrating peptide (CPP) were introduced into human fibroblasts. The
Kim et al., 2009
resultant cells (iPSCs) were similar to human embryonic stem cells in terms of morphology
and markers and were maintained for 35 passages. Moreover, they were capable of germ layer
formation in vitro and formed teratomas in vivo.

20

The risk of introducing potential harmful virally-mediated genetic material is totally eliminated
in this method. Apart from its safety, it is faster and avoids the time consuming selection
of potentially integration-free iPSCs. Lastly, research and/or industrial centers that have
Zhou et al., 2009
established recombinant protein production systems can use this method to produce iPSCs
from these chemically-defined reprogramming proteins in a cost-effective manner.

Stadtfeld et al., 2008

Woltjen et al., 2009
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21

Nonintegrating synthetic RNA has been used to efficiently differentiate RNA-iPSC pluripotent
stem cells (RiPSCs) into mature myogenic cells. This approach is safer than viral/other genetic
approaches and the efficiency is also higher (approximately 2%, better by two orders of
magnitude). Embryonic stem cell-like colonies appeared in 17 days in contrast with the 4 week
period for viral-mediated approaches. The in vitro transcript had a 5’ guanosine cap, 5’ (with Warren et al., 2010
a strong Kozak translational initiation signal sequence) and α-globin 3’ UTR to improve its
half-life and its translational efficiency. This construct was shown to bypasses innate antiviral
responses. The kinetics and efficiency of reprogramming was better (with a range of about
~1%–4.4%) without genomic integration.

22

miRNA-Based strategies can improve the efficiency of the process by two orders of magnitude.
This reprogramming was demonstrated by the formation of iPSCs (induction of Oct4
expression) following the introduction of miRNA302 (miR302/367 cluster) in both mouse
Anokye-Danso et al., 2007
and human somatic cells. Efficiency of this reprogramming process was also dependent on the
decreased expression of HDAC2.

23

Another paper provided corroborative evidence for the involvement of specific microRNAs. In
this regard, a combination of miRNAs (mir-200c plus mir-302s and mir-369s family of mature
Miyoshi et al., 2011
double stranded microRNAs (miRNAs)) was involved in the reprogramming process. This
method has the obvious advantage of not having to employ viral-based strategies.

zinc finger nuclease (ZFN)-mediated targeted correction
of the LRKK2 G2019S mutation in iPSCs reversed the
damage in the mitochondrial DNA. The damage was
undetectable in differentiated neuroprogenitor and
neural daughter cells (Sanders et al., 2014). Modeling of
late-onset disease (e.g., PD) requires changes in iPSCs
(embryonic stem cell-like cells) that can mimic the disease
phenotype in a better manner, especially in the context of
aberrations in mechanisms pertaining to reactive oxygen
species (ROS) levels (Campos et al., 2014). Furthermore,
the introduction of the progerin gene (a truncated form
of LMNA) in fibroblast-derived iPSCs helped in the
manifestation of cell-based aging-related markers (Müller
et al., 2012). An improved understanding of the signal
transduction pathways can help in refining the protocols
for enhancing the efficiency and extent of reprogramming.
Comparison of the protocols for the BMP/TGF-βmediated signal inhibition versus FGF2 signaling has
provided mechanistic details that can serve to enhance
the reprogramming process in human umbilical cord
blood-derived iPSCs. Specifically, the former pathway is
better than the latter in terms of the percentage of tyrosine
hydroxylase neurons and the dopaminergic induction of
these stem cells. Furthermore, 3 weeks after transplantation,
proliferating cells with a tumor-like outgrowth in 2 out
of 4 animals were observed when the FGF-2 signalingmediated neural induction protocol was used (Effenberg
et al., 2015). While it is widely accepted that iPSCs offer
an unprecedented opportunity to develop patient-specific
disease models and help in drug testing, the possibility
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of a few undifferentiated iPSCs becoming tumorigenic
has led researchers to develop transdifferentiation-based
strategies (lineage-specific reprogramming) (Lopez-Leon
et al., 2014).
3.2. Hematological models
A protocol was developed wherein skin biopsies were taken
from a patient with Fanconi anemia (FA). Subsequently,
the defect was corrected in human fibroblasts and/or
keratinocytes following which viral transduction of TFs
(Oct4, Sox-2, and Klf-4) was performed. This method can
be extended to treat other disorders amenable to genecorrected reprogrammed iPSCs (Raya et al., 2010; Focosi et
al., 2014). Mechanistically, reprogrammed cells exhibited
activation of aberrant signals in the FA pathway (involved
in genome maintenance and its protection against crosslinking agents). Such molecular events may lead to
DNA-double strand breaks, senescence, and a decrease
in reprogramming efficiency in both murine and human
cells. However, genetic complementation of the defect can
result in cells with a normal karyotype with a restoration of
reprogramming efficiency and reduction in the senescent
phenotype. These cells also undergo differentiation into
cells of the hematopoietic lineage (Müller et al., 2012; Rio
et al., 2014). Apart from the genes in the FA pathway, Brca2
protein has also been implicated in DNA repair processes,
specifically homology-redirected recombination. Brca2
gene complementation in MEFs aided in the generation of
iPSCs with a genetically stable, disease-free phenotype and
could be differentiated into hematopoietic cells despite
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having a relatively lower efficacy and limited engraftment
potential. Apart from these limitations, other genetic
alterations, not observed in the uncorrected parental cells,
were detected by karyotyping and comparative genome
hybridization (CGH) (Navarro et al., 2014). A more recent
strategy, possibly for the first time, involved the use of
ZFNs and nonintegrating lentiviral vectors with resultant
improvements in the specificity and efficiency of gene
targeting (40% after 42 days) in the AAVS1 safe harbor locus
in fibroblasts from FA patients. Moreover, the genetically
corrected reprogrammed cells were differentiated to
produce disease-free hematopoietic stem cells (HSCs) (Liu
et al., 2014). Disease modeling was made possible by the
generation of FA cell lines from human embryonic stem
cells and iPSCs. It was possible to identify a defect earlier
in the heamangiogenic progenitors and hence, such iPSCs
improved our mechanistic understanding, at least, in part,
of the FA pathology (Suzuki et al., 2015) and underscored
the importance of certain proteins in the reprogramming
process (Yung et al., 2013). Moreover, these cell lines
provided a system for the testing of agents that promoted
hematopoietic differentiation. Furthermore, these cell
lines could be used to test agents that rescued FA cells and
converted them into cells with the normal phenotype (Liu
et al., 2014). Shwachman–Bodian–Diamond syndrome
(SBDS) is an autosomal recessive syndrome. This syndrome
is associated with enzyme-mediated autodigestion (Kelley
et al., 2013) and is linked to defects in the differentiation of
pancreatic and hematopoietic cells. iPSCs generated from
such patients were known to show increases in apoptotic
phenomena and increased secretion of proteases in culture
supernatants. This extracellular protease increase was
shown to be linked to the deficits in exocrine pancreatic
and hematopoietic differentiation in vitro since restoration
of the normal phenotype could be accomplished by SBDS
gene expression or by the use of protease inhibitors
(Tulpule et al., 2013). A combination of reprogramming
methods to generate iPSCs and gene targeting using
lentiviral vectors has resulted in the development of models
demonstrating their curative potential. This approach has
been extended successfully to clinical trials. However,
certain areas like stoichiometry between endogenous and
transgenic hemoglobin (since β globin gene mutations
occur at different sites) and safety due to the possibility
of insertional mutagenesis and myeloablation-mediated
toxicity should be focused upon to improve the efficacy
and safety of this therapeutic strategy for correction of this
monogenic disease in sickle cell anemia patients (Dong
et al., 2013). Patient-derived iPSCs with 2 mutated beta
globin alleles were obtained. The heterozygous condition,
with one copy of the gene corrected, was obtained in
a 2 step procedure. The first step involved the use of a
plasmid encoding a drug resistant gene flanked by LoxP

sites. Precise homologous recombination (HR) with ZFNs
ensured the conversion/correction of one allele of the β
globin gene. The second step involved the Cre recombinase
excising the cointegrated selection gene in the intronic
region, thereby reversing the suppressed gene expression
at the transcriptional level. Gene expression was around
25%–40% following erythrocyte differentiation in
comparison with the wild type levels (Zou et al., 2011). A
publicly available open source approach (the oligomerized
pool engineering method) was adopted to identify 3 ZFNs
that could increase the hitherto reported decrease in
HR frequency in iPSCs from sickle cell anemia patients.
Such ZFNs enabled the transgene-free correction of a
monogenic disorder mutation. The resultant cells were
fully pluripotent and had a normal karyotype following
removal of the reprogramming factors and the selectable
drug resistant gene markers (Sebastiano et al., 2011).
Advances in gene editing have been adapted to precisely
correct such errors in the DNA sequence in iPSCs. Success
also depends on gene expression being regulatable in a
cell-specific condition-dependent manner (Jazwa et al.,
2013).
β-Thalassemia is a common genetic disease due to
mutations or deletions in the β-globin gene. Research is
ongoing in the area of gene therapy since it is a promising
approach for treatment of this disorder (Finotti et al.,
2015). A study performed in China demonstrated HRmediated hemoglobin subunit beta (HBB) gene correction
in iPSCs derived from human fibroblasts isolated from a
2-year old β-thalassemia patient. Specifically, the gene
corrected was a 41/42 deletion in the human globin gene.
The corrected cells were able to produce normal human β
globin in a mouse model (Wang et al., 2012). iPSCs derived
from β-thalassemia could be genetically corrected with
lentiviral-mediated gene transfer and it was found that
the integration of the vectors occurred at common sites
(non-randomly) for iPSCs produced from both isogenic
and nonisogenic patients. No oncogene was selectively
activated (Tubsuwan et al., 2013). More recently, advances
in genome editing using transcription activator-like
effector nucleases (TALEN)/PB or clustered regularly
interspaced short palindromic repeats (CRISPR))/Cas9based tools have served to improve the precision of gene
targeting with minimal or no off-shore target effects.
It has been shown that TALEN with a PB transposon
vector could produce corrected cells (intron 2 mutation
site IVS2-654) at a higher homologous gene frequency
in comparison with the CRISPR/Cas9. Furthermore, β
globin gene transcription was higher in the differentiated
erythroblast progeny of such iPSCs using a OP9 coculture
system (Xu et al., 2015). Demonstration of the precision
of the gene targeting approach required the analysis of
DNA sequences. Hence, both alleles of the HBB gene were
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corrected by the ZFN/Cre recombinase in iPSCs from
amniotic cells. The genetically modified cells were subject
to CGH and whole-exome sequencing. In both steps (iPSC
generation and gene targeting), substantial, but different
genomic variations were observed. Hence, it has to be
ensured that such genetic changes do not have adverse
therapeutic consequences (Ma et al., 2015). Another report
has highlighted the utility of the CRISPR/Cas9 system in
correcting the HBB gene in the generated iPSCs. These
iPSCs had a normal karyotype and were fully pluripotent.
ROS formation was decreased and they exhibited a better
differentiation potential (Song et al., 2015). The Yamanaka
approach of reprogramming fibroblasts was adopted to
generate iPSCs from bone marrow stromal cells from
β-thalassemia patients. The gene expression profile
resembled that of hESCs following lipofection of mRNA
for TFs (OSKM +Lin28). However, the low hematopoietic
potential (10% & CD34+) and a decreased colony forming
ability warranted the need for further improvements in the
protocols for optimized patient-specific autologous iPSCs
(Varela et al., 2014). Another group provided further
evidence for the CRISPR/Cas9/PB transposon system
being an effective gene editing tool in terms of restoring
HBB expression in iPSCs from β-thalassemia patients.
No unwanted residual genetic footprint was observed in
these patient-derived stem cell-like cells (Xie et al., 2014).
Again, TALEN-based universal gene correction was
demonstrated in integration-free β-thalassemia iPSCs in
situ with no off-shore effects. The pluripotent iPSCs with
a normal karyotype retained their differentiation potential
as demonstrated by the formation of progenitor cells and
erythroblasts cells of the hematopoietic lineage as well as
by their expression of normal globin expression (Ma et al.,
2013).
4. Microenvironment models for hiPSC
Classical evidence for the role of the microenvironment in
terms of elasticity/stiffness is provided by the observation
that the beating of the cardiomyocytes is optimal when it
is cultured on a matrix with an elasticity of 1–2 kPa. This
elasticity mimics that of an E4 embryo. The cell-intrinsic
mechanosensitivity observed with sparsely cultured
cardiomyocytes was also observed by those differentiated
cells produced from iPSCs (Majkut et al., 2013). Another
line of evidence was provided by the use of 4% polyethylene
glycol (PEG)–96% polycaprolactone (PCL) for culturing
cardiomyocytes derived from iPSCs. Culturing
cardiomyocytes in such a microenvironment resulted in
improved contractility and mitochondrial function apart
from the switch of the fetal troponin to the adult form
(Chun et al., 2015). In order to confer better liver functions
for a longer period of time in vitro, semiconductor-driven
microfabrication tools have been used to precisely control
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the microenvironment (Davidson et al., 2015). A 10day old culture of patient embryoid body-derived iPSCs
on concave hydrogel structures resulted in these cells
differentiating into the 3 germ layers and forming cavities
(another sign of differentiation). These results provided
evidence of the important role of the microenvironment
mimicking that found around the developing embryonic
stem cells in vivo (Hribar et al., 2015). Culture conditions
were created wherein the microenvironment existing
in the aorta-gonad-mesonephros (AGM) region was
mimicked using a combination of approaches. They were
embryonic stem cells grown on primary AGM explant
cultures or on AM20-1B4, a stromal cell line. This resulted
in the increased production of embryonic stem cellderived HSC progenitor cells in both experimental systems
(Krassowska et al., 2006). A biodegradable polymeric
nanostructure was used to mimic the extracellular matrix
niche and provided mechanical support for the optimal
growth of iPSCs as a multilayered 3D spheroid culture. In
the absence of this material, the cultures were converted
back to the 2D monolayer. This approach has tremendous
ramifications since it may aid in the coupling of signal
transduction pathways involved in the formation of iPSCderived organs (Alamein et al., 2014). The content of PEG
on polymeric films was modulated to improve the human
mesenchymal stem cells differentiating into osteoblasts
(Vega et al., 2012). In certain cases, (e.g., spinal cord injury)
among other factors, the complex microenvironment may
limit the ability of the produced iPSCs to be successfully
engrafted. For example, in an immune-suppressed animal
model for contusion spinal cord injury, iPSCs derived
neural progenitor cells could not restore functionality
(Pomeshchik et al., 2014). Poly dimethyl siloxane (PDMS)patterned substrates that were plasma treated and coated
with vitronectin were developed. These modified substrates
provided a better microenvironment for cell adhesion
and expressed markers for the undifferentiated state
for 7 days (Yamada et al., 2014). The microenvironment
also includes cell-cell interactions and factors released
from them. Reprogramming of fetal fibroblasts may be
favored due to cell-cell contact and/or factors produced
from ovarian cells (Lim and Gong, 2013). The same
concept applies to the development of hepatocytes from
iPSCs, which, when differentiated into hepatocytes, can
be used as disease models. Moreover, they can be used
to test drugs and can also be differentiated, subsequent
to their genes being corrected in iPSCs. In this regard,
the role of the microenvironment is pivotal (Subba Rao
et al., 2013). It is worthy of mention that apart from
the mechanical and biochemical microenvironmental
cues, cardiac stimulation by electrical means served as a
positive factor in enhancing the differentiation of iPSCs
into cardiomyocytes in vitro (Dai et al., 2013). Paracrine
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factors in the ischemic microenvironment enhanced new
blood vessel formation and increased the survival of the
introduced cardiomyocytes in mice with myocardial
infarction. These results were obtained subsequent to
the transplantation of endothelial cells produced from
reprogrammed porcine stromal cells (Gu et al., 2012).
5. Drug discovery and screening: focus on neurological
and hematological disorders
The differentiated cardiomyocytes and hepatocytes from
patient-specific iPSCs can be used as cell-based drug testing
models that can potentially resolve toxicity issues, thereby
possibly reducing the attrition rate in drug testing during
clinical trials. This aspect is relevant since 30% of the drugs
fail due to their toxicity to vital organs like the heart or
the liver (Singh et al., 2015). The same technology involved
in iPSC generation could be applied to the generation of
cancer stem cell-like cells. Such cells were tested with
compounds (e.g., Withaferin A) that can inhibit the growth
and/or eliminate these stem cells (Krishnan, 2015a). Such
a strategy can be extended to the development of a highthroughput screening (HTS) platform for the testing of
novel anticancer drugs that can specifically target cancer
stem cells, an important contributor to the observed
recurrences/relapses in cancer patients (Nishi et al., 2014).
The iPSCs from the fibroblasts of familial Alzheimer disease
(AD) patients were differentiated into neurons. These
cells, with mutations in the presenilin genes, exhibited
an increase in amyloid β42 secretion. Such cells could be
tested for the development of promising drug candidates
like the secretase inhibitors and modulators (Yagi et al.,
2011). This cell-based stratification model also provides
the drug hunter an opportunity to identify the right subset
of patients (in both familial and sporadic AD) for which
a particular drug may be effective (Kondo et al., 2013). In
another example, iPSCs carrying mutations in the TDP-43
were generated. The mutant protein levels were increased
in the iPSC-derived differentiated motor neurons. This
biomolecule was insoluble in detergent. This protein was
bound to a spliceosomal factor (SNRBP2). Further, the
cytosolic aggregates and shorter neuritis were respectively
similar to what was observed in the postmortem human
ALS tissue and in a zebrafish model. Last but not least,
this cell-based model system provided a proof-of-concept
approach in terms of testing (anacardic acid, a histone
acetyltransferase inhibitor) a compound that can reverse
the pathology at the cellular level (Egawa et al., 2012).
Apart from human stem cells, wild-type and mutant SOD1
mouse embryonic stem cells may be differentiated into
motor neurons. Such differentiated cells may be used to
screen and select compounds with the potential to reverse
this form of motor neuronal cell death. It was reported
that Kenpaullone was able to inhibit two kinases: glycogen

synthase kinase-3 and hepatocyte progenitor kinase-like/
germinal center kinase-like kinase; however, Olesoxime
and Dexpramipexole failed to show activity (Yang et
al., 2013). The human iPSC (hiPSC)-derived neurons
from schizophrenia (SCZD) patients had alterations in
glutamate receptor expression and PSD-95 protein levels.
Their neurite connectivity was decreased with aberrations
in both Wnt and cyclic adenosine monophosphate
pathways. The importance of modeling this phenotype
was demonstrated by their reversal using Loxapine (an
antipsychotic) (Brennand et al., 2011). iPSCs from skin
fibroblasts of a SCZD patient were made to differentiate
into neural cells. These cells had higher ROS levels and
their oxygen consumption extramitochondrially was also
higher than comparable controls. The elevated ROS levels
could be brought back to normalcy using Valproic acid,
again validating the approach of developing differentiated
disease models from autologous patient-specific cell based
pathology models (Paulsen Bda et al., 2012).
Spinal muscular atrophy, an autosomal recessive
disease, results in the loss of the α motor neurons in the
spinal cord and is considered to be one of the leading
genetic causes of mortality among infants. This loss has
been attributed to a decrease in the level of survival motor
neuron 1 protein (SMN1 protein) due to mutations in its
gene (SMN). It has been reported that there are 16 drugs at
various stages of preclinical and clinical drug development;
other strategies involve upregulating the SMA gene using
antisense oligonucleotide-based modulators (Cherry et al.,
2014).
In iPSCs derived from β-thalassemia patients (mutation
in β-41/42-17), novel Valproic acid derivatives have shown
potential in the increased synthesis of fetal hemoglobin at
concentrations that may possibly be close to the clinically
relevant level (Rönndahl et al., 2006).
The iPSCs from individuals afflicted with Hutchinson–
Gilford progeria syndrome exhibited a truncated
farnesylated form of LMNA. The resultant LMNA
C1824T mutant smooth muscle cell showed their
contractile ability following treatment with Carbachol
(Zhang et al., 2011). Mature pancreatic cell types could
be produced following treatment of SBDS-deficient SDSiPSC-1 cells with a cocktail consisting of aprotinin, broad
spectrum protease, lipase, and a pan-caspase inhibitor
from SBDS patients. Moreover, aprotinin was found to
significantly reduce cell death (Tulpule et al., 2013). This
rapidly advancing technology has been based on studies
involving an improved molecular understanding of the
development of iPSCs from relatively more differentiated
cells (Krishnan, 2015b). Apart from their mechanistic
relevance, it has ramifications in regenerative medicine
and the development of small molecules. Such molecules
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can be used in therapy, in addition to their role in
augmenting and/or replacing genetic reprogrammers to
develop these stem cell-like derivatives. Such approaches
would require an improved molecular understanding of
the reprogramming process.

mode of pathogenesis. These iPSC-derived differentiated
progenies may be useful disease models, provided the
microenvironment is mimicked as closely as possible.
Furthermore, such thoroughly validated models can be
used for efficacy safety testing of drugs in the HTS format.

6. Conclusion
The autologous patient-specific iPSCs generated from
easily accessible, biopsied samples from humans provide
scientists with an unparalleled opportunity to develop
and study disease models to better comprehend the
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